PCV13 boosts systemic but not mucosal immunity to pneumococcal serotype 3
- In a nested analysis of the PREVENTING PNEUMO 2 trial, PCV13 vaccination significantly increased serum IgG for pneumococcal serotype 3, with a two-fold rise observed in 93 of 139 participants.
- Between July 28, 2021, and October 3, 2023, 407 participants were included in the serotype 3 challenge analyses and 243 in the serotype 6B challenge analyses.
- PCV13 vaccination significantly increased CPS3-specific and CPS6B-specific serum IgG levels at one month compared to baseline, with p-values less than 0.0001 for both.
- Only CPS6B-specific IgG was detectable in nasal wash samples at one month compared to baseline, with a p-value less than 0.0001.
The publication
In a nested analysis of the PREVENTING PNEUMO 2 trial, PCV13 vaccination significantly increased serum IgG for pneumococcal serotype 3, with a two-fold rise observed in 93 of 139 participants. However, nasal IgG for serotype 3 was detected only after challenge in participants who acquired carriage, suggesting limited mucosal protection.
Who the findings apply to
The study included healthy adults aged 18 to 50 years who participated in the parent PREVENTING PNEUMO 2 trial.
Participants had received PCV13, PPV23, or placebo in the parent trial and were included in assay-specific analyses based on sample availability.
Participants were intranasally challenged with Streptococcus pneumoniae serotype 3 one month after vaccination.
A subgroup of participants was additionally challenged with Streptococcus pneumoniae serotype 6B six months after vaccination.
Why this matters
Pneumococcal serotype 3 remains a common cause of disease despite some direct protection from PCV13. This study assesses whether specific immune responses correlate with protection from experimental carriage. The findings indicate that while systemic responses are robust, the lack of detectable mucosal immunity to serotype 3 may explain reduced protection against carriage acquisition compared to serotype 6B.
What the study found
Between July 28, 2021, and October 3, 2023, 407 participants were included in the serotype 3 challenge analyses and 243 in the serotype 6B challenge analyses.
PCV13 vaccination significantly increased CPS3-specific and CPS6B-specific serum IgG levels at one month compared to baseline, with p-values less than 0.0001 for both.
Only CPS6B-specific IgG was detectable in nasal wash samples at one month compared to baseline, with a p-value less than 0.0001.
A more than two-fold increase in CPS3-specific IgG concentration was seen in 93 (67%) of 139 participants who received PCV13 and 46 (51%) of 91 participants who received PPV23.
A more than two-fold increase in CPS6B-specific IgG concentration was seen in 103 (96%) of 107 participants who received PCV13 and 58 (79%) of 73 participants who received PPV23.
PCV13-induced CPS3-specific memory B cells were associated with protection from serotype 3 carriage acquisition, but their frequency rapidly declined.
What the result does not establish
Nasal CPS3-specific IgG was detected only after serotype 3 challenge in participants with pneumococcal carriage, indicating low mucosal immunity.
CPS3-specific memory B cell frequencies declined rapidly after vaccination.
The study was an exploratory analysis nested within a phase 4 human pneumococcal challenge trial.
The interpretation suggests that low mucosal immunity to serotype 3 might contribute to reduced protection against carriage acquisition, but this is an association rather than a definitive causal mechanism.
Authors’ conclusion
“PCV13 vaccination induced systemic humoral immune responses to both serotypes but they differed in magnitude, duration, and tissue distribution. The low mucosal immunity to Spn3 might contribute to reduced protection against Spn3 carriage acquisition.”
Trial registration
Registered with the ISRCTN registry as ISRCTN15728847. ENCLAI does not hold this registry record, so its details are not shown; follow the link to read it.
| Registered title | PREVENTING PNEUMOcoccal Disease Through Vaccination (Study 2) (Pneumo 2) |
|---|---|
| Registry status | Phase 4, interventional, unknown |
| Lead sponsor | Liverpool School of Tropical Medicine |
| Registered size | 516 participants — planned enrolment (estimate). The abstract reports: 407 participants |
| Where | 1 site in 1 country (United Kingdom) |
| Registered primary outcome |
|
- Start: Jul 2021
- Primary completion: Jul 2023 (estimated; this date has passed — check the registry)
- Completion: Dec 2023 (estimated; this date has passed — check the registry)
- Paper published: Sep 2026
ClinicalTrials.gov record as held by ENCLAI, last updated Jan 2023. The registry status may have changed since; the link shows the current record.
Study and sources
Evaluation of the effect of serotype on pneumococcal conjugate vaccine-induced immunity: an exploratory analysis of the PREVENTING PNEUMO 2 trial
Early-phase / non-randomised trial · Phase 4 · Lancet Microbe · 2026-09-15
Sources and limitations
- PubMed record PMID 42743942 (PubMed / NLM · 2026-09-29)
- Trial registry NCT04974294 (ClinicalTrials.gov · 2026-09-29)
Related briefings
Follow ENCLAI News
Get new briefings in your news reader. No ENCLAI account needed.
The daily disease brief
One email a day: what changed in official disease reporting worldwide, with the source named for every number. Reported facts only — no forecasts and no interpretation.


